Drug intelligence / Profile preview

OCU510

Development stage: Preclinical
Lead developer: Ocugen
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal, Inhalation

Overview

OCU510 is a drug candidate developed by Ocugen. It is part of the OCU500 series, which focuses on novel mucosal vaccine platforms. Specifically, OCU510 is being developed as a seasonal vaccine, likely targeting respiratory or infectious diseases. As of early 2023, its highest reported development status was preclinical. The precise mechanism of action and target antigens have not been publicly disclosed, but it is positioned within Ocugen's efforts to address infectious and respiratory diseases through innovative vaccine technologies[1][3].

Beyond the preview

Go deeper on OCU510.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCU510.

Explore the full profile